NRx Pharmaceuticals announces expanded access policy for NRX-100

NRx Pharmaceuticals (NRXP) announced its expanded access policy for NRX-100 based on grant of Fast Track designation for NRX-100 in the treatment of suicidal ideation in patients with depression, including bipolar depression. In granting the Fast Track designation, FDA made the determination that NRX-100 has the potential to address an unmet need, based on an assessment of the preliminary data contained in the Fast Track designation request. Accordingly, NRX-100 is available for expanded access to eligible patients.